What should be celebrated? The accelerated pathway, which, even if workable, would apply to a tiny number of medicines, the centralisation of more power in advisory committees and officials, the disinvestment framework, or the new price cuts conveniently presented just before the May Budget?
This is not a messaging campaign and it needs to be taken seriously
January 30, 2024 Latest NewsBioPharmaComment
Latest Video
New Stories
-
Nurse prescribing reform set to expand access to PBS subsidised medicines
July 3, 2026 - - Latest News -
Cartherics emerges as Asia Pacific leader in off-the-shelf immune cell therapy
July 2, 2026 - - Australian Biotech -
Minister looks to be sending a very clear message about these therapies and the PBS
July 2, 2026 - - Latest News -
The end-game of strong-arming companies over prices at the expense of patients and process
July 2, 2026 - - Latest News -
Commercial outsourcing emerges as a strategic option to patient access
July 1, 2026 - - Latest News -
The minister is following a tried and tested process, but what is the risk in this new world?
July 1, 2026 - - Latest News -
Patient alarm over the potential loss of subsidised access to MS medicines
July 1, 2026 - - Latest News


